Amedisys Stock Analysis, Valuation (NASDAQ:AMED)
Amedisys Analysis Video
View Amedisys stock analysis video. This is our AMED analyst opinion covering the buy and sell arguments for AMED stock.
Amedisys Inc Stock Rating (3.4/5)
Our Amedisys stock opinion is based on fundamentals of the company. This Amedisys stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.
Should you buy AMED stock?
- LTM Net margins were good at 2.7% for Amedisys.
- The lower PS ratio 1.1 for AMED stock versus Medical-Outpatient-Home care industry average of 5 is a positive for the company.
- Amedisys generates a high return on invested capital of 6.7%.
- Return On Equity (ROE) which is a measure of the company's profitability, looks great for Amedisys at 8.6%.
- The company has a healthy free cash flow margin of 8.8%.
Should you sell AMED stock?
- Revenue declined at a CAGR of -0.2% over the last 5 years.